Novel Fabrication of Long Term Blood Oxygenators

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$171,375.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL071321-01A2
Award Id:
70902
Agency Tracking Number:
HL071321
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
325 WATER STREET, WILMINGTON, DE, 18904
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
STUART NEMSER
(302) 999-7996
stuart.nemser@compactmembrane.com
Business Contact:
NADINE CRAGG-LESTER
(302) 999-7996
NADINE.LESTER@COMPACTMEMBRANE.COM
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Long-term blood oxygenator (BO) therapy requires non-porous coatings to limit BO wet out. Compact Membrane Systems (CMS) has identified novel materials that can minimize wet out while simultaneously maintaining needed gas-liquid transport of gases. In order for these novel materials to be of significant commercial value they must be able to easily integrate into existing commercial BO operations. Present fabrication capabilities with these novel materials are significantly limited. In-situ introduction of non-porous coatings is presently unacceptable due to fiber-fiber bridging. Coating of individual fibers prior to module fabrication while having some potential has many downstream problems and is not easily integrated into existing BO manufacturing lines. Discussions with experts in the field have identified a number of blood oxygenation applications that can take advantage of the novel product. These applications include ARDS (Acute Respiratory Distress Syndrome), ECMO (Extracorporeal Membrane Oxygenators) cardiac and respiratory patients and high risk cardiac surgical procedures. CMS has identified novel procedure to easily integrate their novel material into existing BO fabrication systems. In Phase I CMS will demonstrate its novel procedure using CMS's high gas flux non-porous non-wetting membrane. Phase I will include in-vitro and in-vivo tests which show CMS process provides BO with needed wet out resistance while maintaining gas exchange into and out of blood and equally as important is easily integrated into commercial BO operations. Bio-compatibility testing will be completed in Phase I. Phase I quantitatively defines program objectives and alternative strategies if needed. In-vivo testing will demonstrate proof of feasibility consistent with Phase I funds, and enhance our ability for a targeted Phase II program. Pre-clinical testing and key partners will enhance our ability to rapidly move to clinical testing.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government